Phaseline

Companies › Currax Pharmaceuticals

Currax Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 4; Metabolic and endocrine; next expected readout Jan 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bupropion
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4ObesityJan 2029
Naltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4ObesityJan 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06098079NaltrexonePhase 4ObesityMetabolic and endocrineJan 2029
NCT06098079BupropionPhase 4ObesityMetabolic and endocrineJan 2029

Targets

OPRK1 (1) OPRD1 (1) OPRM1 (1) SLC6A3 (1) SLC6A2 (1)

Companies with the same targets

Axsome Therapeutics Trevi Therapeutics AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Adneuris Therapeutics Alkermes Boulder Care Inventage Lab. Otsuka

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.